167 related articles for article (PubMed ID: 31881245)
1. Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
Okumu DO; Aponte-Collazo LJ; Dewar BJ; Cox NJ; East MP; Tech K; McDonald IM; Tikunov AP; Holmuhamedov E; Macdonald JM; Graves LM
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129507. PubMed ID: 31881245
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
Ito T; Tanaka H; Kimura A
Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
[TBL] [Abstract][Full Text] [Related]
3. BIRC6 mediates imatinib resistance independently of Mcl-1.
Okumu DO; East MP; Levine M; Herring LE; Zhang R; Gilbert TSK; Litchfield DW; Zhang Y; Graves LM
PLoS One; 2017; 12(5):e0177871. PubMed ID: 28520795
[TBL] [Abstract][Full Text] [Related]
4. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
Zimmerman EI; Dollins CM; Crawford M; Grant S; Nana-Sinkam SP; Richards KL; Hammond SM; Graves LM
Mol Pharmacol; 2010 Nov; 78(5):811-7. PubMed ID: 20693279
[TBL] [Abstract][Full Text] [Related]
5. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
[TBL] [Abstract][Full Text] [Related]
6. Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Wang Q; Zimmerman EI; Toutchkine A; Martin TD; Graves LM; Lawrence DS
ACS Chem Biol; 2010 Sep; 5(9):887-95. PubMed ID: 20583816
[TBL] [Abstract][Full Text] [Related]
7. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
Smith PG; Tanaka H; Chantry A
Oncotarget; 2012 May; 3(5):518-24. PubMed ID: 22643838
[TBL] [Abstract][Full Text] [Related]
8. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
9. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
Obr A; Röselová P; Grebeňová D; Kuželová K
PLoS One; 2014; 9(9):e107367. PubMed ID: 25198091
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
13. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
Liu J; Zhao XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
[TBL] [Abstract][Full Text] [Related]
17. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Tabe Y; Jin L; Iwabuchi K; Wang RY; Ichikawa N; Miida T; Cortes J; Andreeff M; Konopleva M
Leukemia; 2012 May; 26(5):883-92. PubMed ID: 22005789
[TBL] [Abstract][Full Text] [Related]
18. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
